ERAS vs INDV: stock comparison and AI forecast
Erasca, Inc. (ERAS) and Indivior Pharmaceuticals, Inc. (INDV) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
ERAS Erasca, Inc.
- Price
- $13.27 +27.6% · 6M
- Market Cap
- $4.64B
- P/E Ratio
- –
- Size
- mid-cap
- AI Forecast
INDV Indivior Pharmaceuticals, Inc.
- Price
- $35.37 -3.8% · 6M
- Market Cap
- $4.17B
- P/E Ratio
- 8.6x
- Size
- mid-cap
- AI Forecast
- NO CURRENT FORECAST
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- ERAS is 1.1 times larger than INDV by market capitalization ($4.64B against $4.17B).
- Over the last six months ERAS returned +27.6% and INDV -3.8%.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | ERAS | INDV |
|---|---|---|
| Market Cap | $4.64B | $4.17B |
| P/E Ratio | – | 8.63x |
| P/B Ratio | 12.83x | – |
| EPS | $-0.46 | $4.10 |
| Book Value/Share | $1.03 | – |
| Revenue/Share | – | $11.63 |
| FCF/Share | $-0.28 | $0.26 |
Profitability & Margins
| Metric | ERAS | INDV |
|---|---|---|
| ROIC | -75.4% | – |
| Gross Margin | – | 84.8% |
| Operating Margin | – | 41.0% |
| Net Margin | – | 32.1% |
| EBT Margin | – | 39.6% |
| Tax Rate | – | 16.5% |
Financial Health
| Metric | ERAS | INDV |
|---|---|---|
| Current Ratio | 8.29x | 0.61x |
| Quick Ratio | – | 0.50x |
| D/E Ratio | 0.20x | – |
| Financial Leverage | 1.20x | – |
| Interest Coverage | – | 6.8x |
| Working Capital | $245M | -$501M |
Cash Flow
| Metric | ERAS | INDV |
|---|---|---|
| Operating Cash Flow | -$98M | $96M |
| Free Cash Flow | -$98M | $31M |
| Capital Spending | -$60K | -$65M |
| OCF Growth YoY | – | -52.7% |
| FCF Growth YoY | – | -79.8% |
| FCF/Sales | – | 2.3% |
| CapEx/Sales | – | 4.7% |
Operational Efficiency
| Metric | ERAS | INDV |
|---|---|---|
| Receivables Turnover | – | 5.0x |
| Inventory Turnover | – | 1.4x |
| Fixed Assets Turnover | – | 7.8x |
| Days Sales Outstanding | – | 73 days |
| Days Inventory | – | 261 days |
| Payables Period | – | 49 days |
| Cash Conversion Cycle | – | 285 days |
Income Statement
| Metric | ERAS | INDV |
|---|---|---|
| Total Revenue | – | $1.37B |
| Operating Income | -$303M | $558M |
| Net Income | – | $436M |
| R&D Expense | $109M | $54M |
| SG&A Expense | – | $553M |
| Cost of Goods Sold | – | $208M |
Dividend & Shareholder Information
| Metric | ERAS | INDV |
|---|---|---|
| Shares Outstanding | 350M | 118M |
| Net Income Growth | – | 305.6% |
| EPS Growth | – | 1123.9% |
ERAS vs INDV: stock comparison and AI forecast
Which is bigger, ERAS or INDV?
ERAS is 1.1 times larger than INDV by market capitalization ($4.64B against $4.17B).
Which stock performed better over the last six months, ERAS or INDV?
Over the last six months ERAS returned +27.6% and INDV -3.8%.
Which one does Intratio's AI model rank higher, ERAS or INDV?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.